Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.82 (market cap $158.90B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 162.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays a 2.35% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 6 Days on average.
| MRVI | SMFG | |
|---|---|---|
Market Cap | $977.37M | $158.90B |
Volume | 2,742,564 | 1,175,519 |
Sector | Health | Financials |
52-Week High | $9.00 | $27.56 |
52-Week Low | $2.83 | $15.69 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $12.70T |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SMFG trades at $25.21, up 0.72% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beating expectations with $0.50 EPS versus $0.44 expected, while Q4 2025 missed estimates. Revenue grew from $5.07T in 2025 to $6.14T in 2026 with net income margin improving to 27.8%. Analyst consensus shows 75% hold rating with institutional positions shifting recently.
SMFG presents a value opportunity with attractive valuation ratios (P/E 14.9, EV/EBITDA 5.16) and improving profitability, though technical weakness and mixed analyst sentiment suggest near-term caution. The stock faces risks from Japanese interest rate sensitivity and competitive pressures in global banking markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)
Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →
